

Chaney C Kalinich

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2238750/chaney-c-kalinich-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38

papers

2,706

citations

18

h-index

46

g-index

46

ext. papers

4,359

ext. citations

26.5

avg, IF

4.52

L-index

#	Paper	IF	Citations
38	A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice. <i>Journal of Experimental Medicine</i> , 2022 , 219,	16.6	11
37	Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA.. <i>Cell Reports Medicine</i> , 2022 , 3, 100583	18	9
36	Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents.. <i>JAMA Network Open</i> , 2022 , 5, e220935	10.4	2
35	Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons.. <i>Med</i> , 2022 ,	31.7	10
34	Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 variants Alpha and Iota.. <i>Communications Biology</i> , 2022 , 5, 439	6.7	1
33	Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. <i>Nature</i> , 2021 ,	50.4	71
32	Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient. <i>Journal of Infectious Diseases</i> , 2021 ,	7	4
31	Diverse Functional Autoantibodies in Patients with COVID-19 2021 ,		65
30	SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity. <i>Med</i> , 2021 , 2, 263-280.e6	31.7	110
29	Case Study: Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient 2021 ,		2
28	Stability of SARS-CoV-2 RNA in Nonsupplemented Saliva. <i>Emerging Infectious Diseases</i> , 2021 , 27, 1146-1150.2	50.2	21
27	Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States. <i>Cell</i> , 2021 , 184, 2595-2604.e13	56.2	55
26	Delayed production of neutralizing antibodies correlates with fatal COVID-19. <i>Nature Medicine</i> , 2021 , 27, 1178-1186	50.5	65
25	Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2. <i>PLoS Biology</i> , 2021 , 19, e3001236	9.7	85
24	Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient 2021 ,		1
23	Lying in wait: the resurgence of dengue virus after the Zika epidemic in Brazil. <i>Nature Communications</i> , 2021 , 12, 2619	17.4	11
22	Diverse functional autoantibodies in patients with COVID-19. <i>Nature</i> , 2021 , 595, 283-288	50.4	199

21	Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 lineages 2021 ,		4
20	Early introductions and community transmission of SARS-CoV-2 variant B.1.1.7 in the United States 2021 ,		9
19	Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies. <i>PLoS Biology</i> , 2021 , 19, e3001333	9.7	40
18	Global disparities in SARS-CoV-2 genomic surveillance 2021 ,		26
17	Prevention of host-to-host transmission by SARS-CoV-2 vaccines. <i>Lancet Infectious Diseases</i> , 2021 ,	25.5	15
16	Variant abundance estimation for SARS-CoV-2 in wastewater using RNA-Seq quantification 2021 ,		3
15	Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality 2021 ,		41
14	362. Saliva as a Reliable Sample Type for Mass SARS-CoV-2 Testing Strategies. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S284-S284	1	
13	Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States. <i>Cell</i> , 2020 , 181, 990-996.e5	56.2	235
12	Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive collection devices 2020 ,		38
11	Sex differences in immune responses that underlie COVID-19 disease outcomes. <i>Nature</i> , 2020 , 588, 315-320	30.4	556
10	Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets. <i>Nature Microbiology</i> , 2020 , 5, 1299-1305	26.6	380
9	Real-time public health communication of local SARS-CoV-2 genomic epidemiology. <i>PLoS Biology</i> , 2020 , 18, e3000869	9.7	12
8	Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. <i>New England Journal of Medicine</i> , 2020 , 383, 1283-1286	59.2	507
7	Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons		2
6	SalivaDirect™ RNA extraction-free SARS-CoV-2 diagnostics v5		5
5	SalivaDirect: RNA extraction-free SARS-CoV-2 diagnostics v3		2
4	SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity		42

3	Viral dynamics of acute SARS-CoV-2 infection	51
2	SalivaDirect [®] RNA extraction-free SARS-CoV-2 diagnostics v6	4
1	Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity in uninfected and previously infected individuals	11